Emmes Group Teams Up with Health Tech Startup Miimansa AI to Transform Clinical Research

In a significant move set to transform the landscape of clinical research, Emmes Group, a leading specialty tech-enabled global contract research organization (CRO), has announced a multi-year strategic partnership with Miimansa AI. The collaboration, which includes the acquisition of Miimansa's Clinical Entity Modeling tools, aims to leverage advanced large language modeling (LLM) techniques and generative AI to revolutionize clinical research processes at Emmes.

The partnership comes at a time when artificial intelligence is poised to reshape various aspects of healthcare, including clinical research. Emmes Group is actively enhancing its technology platform, Veridix AI, and the acquisition of Miimansa's Clinical Entity Modeling technology is expected to play a crucial role in accelerating the development of state-of-the-art automated text processing solutions tailored for clinical research.

Key focus areas of the partnership include creating capabilities for swift and accurate processing of vast amounts of clinical data, as well as enabling text-to-text transformations such as protocol authoring and medical writing. These advancements are anticipated to significantly reduce the time and costs associated with manual data handling and analysis in clinical trials.

Sastry Chilukuri, CEO of Emmes Group, expressed enthusiasm about the partnership, stating, "We are excited to partner with Miimansa AI to bring cutting-edge AI technology to the forefront of clinical research. The clinical entity modeling tools acquired through our partnership will accelerate development and adoption of Emmes Groups' Gen AI platform, named Concord, to drive faster, better and more efficient clinical trials."